Skip to main content
News

cfDNA Methylation Analysis Demonstrates 94.7% Sensitivity for Non-EML4-ALK Fusions in Non-Small Cell Lung Cancer

Edited by 

Clinical Summary: 

  • Design/Population: This validation study evaluated a cell-free DNA (cfDNA) methylation-based fusion epigenotyping classifier for detecting non-EML4-ALK fusions in non-small cell lung cancer (NSCLC), using 132 ALK fusion-positive clinical samples and 406 ALK fusion-negative samples, alongside simulated genomically missed fusion cases.

  • Key Outcomes: The classifier demonstrated 94.7% sensitivity and 99.3% specificity for non-EML4-ALK fusion detection, identifying fusions involving 48 partners. In an in silico analysis, the method rescued 20.2% of genomically missed fusion cases, with no high-confidence false-positive calls observed in the validation cohort.

  • Clinical Relevance: These findings support cfDNA methylation-based fusion epigenotyping as a complementary approach to genomic liquid biopsy testing, potentially improving ALK fusion detection and identifying additional patients with NSCLC who may benefit from ALK inhibitor therapy.

Results from a clinical validation study demonstrated that cell-free DNA (cfDNA) methylation-based fusion epigenotyping improved detection of non-EML4-ALK fusions in non-small cell lung cancer (NSCLC), achieving high sensitivity and specificity while identifying additional fusions missed by genomic-based liquid biopsy methods.

These findings were presented by Laura Tung, PhD, Guardant Health, Palo Alto, California, at the Association for Molecular Pathology (AMP) Annual Meeting and Expo. 

In this study, investigators developed a cfDNA methylation-based fusion epigenotyping classifier designed to distinguish ALK fusion-positive from ALK fusion-negative NSCLC samples using methylation profiles and genomic molecule support. The approach was developed to address limitations of genomic fusion detection in liquid biopsy, including short sequencing read lengths, breakpoint heterogeneity, and challenges associated with capture probe design.

Building on previous validation of the method for EML4-ALK fusion detection, the current analysis focused on non-EML4-ALK fusion partners, which account for approximately 10% to 15% of ALK-positive NSCLC cases. The analysis included Guardant360 Liquid cfDNA samples with an epigenomic tumor fraction greater than 0.1%.

To evaluate detection sensitivity, investigators analyzed 132 independent clinical NSCLC samples with non-EML4-ALK fusions, including 12 samples with fusions detected in paired tumor tissue and 120 samples with fusions genomically identified in cfDNA.

Specificity was evaluated using 406 independent clinical NSCLC samples with paired tissue and cfDNA testing, both negative for ALK fusions. Investigators also used in silico simulations of 129 clinical non-EML4-ALK fusion cases to assess whether the epigenotyping classifier could identify fusions missed by genomic detection methods.

For non-EML4-ALK fusions involving 48 fusion partners, the classifier achieved a sensitivity of 94.7%, correctly identifying 125 of 132 fusion-positive samples. Specificity was 99.3%, with 403 of 406 ALK fusion-negative samples correctly classified.

Among high-confidence fusion calls, defined by a probability exceeding a threshold corresponding to 99.7% specificity or the presence of partial genomic evidence, no false-positive results were observed among the 406 ALK fusion-negative samples.

In the simulated genomically missed fusion cases, the classifier rescued 20.2% of non-EML4-ALK fusions, identifying 26 of 129 cases that would otherwise have been missed by genomic-based detection.

These findings suggest that incorporating methylation-based fusion epigenotyping into liquid biopsy workflows may improve detection of ALK rearrangements beyond conventional genomic methods.

The investigators concluded that cfDNA methylation-based fusion epigenotyping demonstrated high sensitivity and specificity for non-EML4-ALK fusion detection, supporting its potential to complement genomic liquid biopsy testing and expand identification of patients with NSCLC who may be eligible for ALK inhibitor therapy.


Source: 

Tung L, Valouev A, Odegaard J, et al. Cell-free DNA methylation-based fusion epigenotyping increases sensitivity of ALK fusion detection in NSCLC liquid biopsy. Presented at the AMP Annual Meeting and Expo. November 10-14, 2026; Seattle, Washington. Abstract IO67.